Edition:
United States

People: Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

5.35USD
21 Sep 2018
Change (% chg)

$0.07 (+1.33%)
Prev Close
$5.28
Open
$5.27
Day's High
$5.38
Day's Low
$5.25
Volume
221,706
Avg. Vol
121,610
52-wk High
$9.69
52-wk Low
$4.44

Matis, Louis 

Dr. Louis Matis, M.D., is Senior Vice President and Chief Development Officer of Pieris Pharmaceuticals, Inc. Prior to joining Pieris, Dr. Matis served since June 2011 as Executive Director, Strategic Evaluation at Alexion Pharmaceuticals, where he also served from 1993 to 2000, during which time he advanced to the position of Chief Scientific Officer and had a leading role in discovering the first-in-class complement inhibitor monoclonal antibody Soliris® (eculizumab). Before re-joining Alexion in 2011, Dr Matis served as CEO of CGI Pharmaceuticals, Inc. from 2000 to 2006, and of the Immune Tolerance Institute from 2007 to 2010. From 1977 until joining Alexion in 1993, Dr. Matis held senior research and clinical positions at the National Cancer Institute (NCI), National Institutes of Health (NIH), in Bethesda, MD, and the FDA Center for Biologics Evaluation and Research (CBER). Dr. Matis holds a B.A. from Amherst College and an M.D. from the University of Pennsylvania, Perelman School of Medicine, receiving his clinical training in Internal Medicine at the University of Chicago Hospitals and Clinics, and in Medical Oncology at the NCI. Dr. Matis is the author of over 120 publications in major scientific and medical journals and is a co-inventor on multiple patents.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --